Capricor Therapeutics (CAPR): H.C. Wainwright Confirms Buy Recommendation With 805% Price Potential - Panic Reaction may Represent Entry Opportunity!
Reading Time: 4 minutes
Capricor Therapeutics (CAPR) is an emerging biotechnology company specializing in the development of transformative cell and exosome-based therapeutics for the treatment of rare diseases. At the heart of the company is Deramiocel (also known as CAP-1002), a leading cell therapy candidate for the treatment of Duchenne muscular dystrophy (DMD). The clinical pipeline of the company, particularly regarding Deramiocel, holds significant potential. 4-year data from the Open HOPE-2 extension study with Deramiocel in Duchenne Muscular Dystrophy On...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
